-
Mashup Score: 0An electronic shared decision-making app to improve asthma outcomes: a randomized controlled trial - 1 year(s) ago
Shared decision making (SDM) incorporates patient values and preferences to optimize asthma management decisions. Available asthma SDM aids primarily focus on medication selection.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality - 1 year(s) ago
ASCO-Friends study: sponsors say COVID-19–era trial flexibilities had minimal impact on treatment trial data integrity.
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
@ASCO & @CancerResrch just published a report that indicates strategies implemented during the pandemic to provide greater flexibility in trial conduct may reduce the burden of #trial participation for #patients & sites with limited adverse consequences. https://t.co/FXq0CAyLw8 https://t.co/MzAOeLM6uk
-
-
Mashup Score: 2Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM) - 2 year(s) ago
Mastocytosis is a rare clonal disorder of mast cells, manifestations of which are protean and can include anaphylaxis, urticaria/angioedema, malabsorption, and osteoporosis. Although there is no known cure, treatments include antimediator medications and cytoreductive therapy.1 More recent treatments include agents targeting the commonly associated mutations in the KIT receptor (CD117), but these can have significant adverse effects.2
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet-
In Current Issue! #Randomized #controlled #trial of #omalizumab in #treatment-resistant #systemic and #cutaneous #mastocytosis (ROAM) https://t.co/ATkPmRmjXS https://t.co/sb3L56EYIU
-
-
Mashup Score: 0Single high-sensitivity troponin sample below the limit of detection to safely rule out NSTEMI-ACS: is this enough? - 2 year(s) ago
This editorial refers to ‘Troponin in early presenters to rule out myocardial infarction’, by M.T.H. Lowry et al., https://doi.org/10.1093/eurheartj/ehad376.
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Single high-sensitivity troponin sample below the limit of detection to safely rule out NSTEMI-ACS: is this enough? Read the latest Editorial in #EHJ: https://t.co/xiJi9V6VEt #troponin #ruleout #MI #HighSTEACS #trial #cardiotwitter @escardio @ESC_Journals https://t.co/2w1X6gaiCx
-
-
Mashup Score: 10Cardiovascular Round Table (CRT) Plenary - 2 year(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiologists, Latest HeadlinesTweet-
Honoured to co-chair this @escardio #CardiovascularClinicalRoundtable w @FaiezZANNAD @TomLuscher We’ll tackle issues that influence #RCT #representativeness, including #trial design, #leadership Outstanding speakers/discussants https://t.co/wQWUbFBgqd https://t.co/URoaLI5wGl https://t.co/zumY3RtmD8
-
-
Mashup Score: 0European Study Finds the Abbott Cardiomems Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations - 2 year(s) ago
May 25, 2023 — New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott’s CardioMEMS HF System resulted in a significant1 improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor. The MONITOR-HF trial also resulted in a significant 44% reduction in heart…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @AbbottCardio #MONITOR_HF is the third randomized, controlled #trial globally to show a significant health benefit for indicated #heartfailure patients: https://t.co/Zhqp8hVBaE
-
-
Mashup Score: 1Real-world outcomes from the EU-PORIA registry of the FARAPULSE Pulsed Field Ablation (PFA) System - 2 year(s) ago
May 22, 2023 — Boston Scientific Corporation announced data supporting use of the company’s key electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. All data were presented at Heart Rhythm 2023, the annual meeting of the Heart Rhythm Society, held in New Orleans from May 19-21. Real-world outcomes from the EU-PORIA registry…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @BSCCardiology Results from #global #trial of the #POLARx #Cryoablation System meet safety and effectiveness endpoints: https://t.co/Et9ZxEOZbK #HRS23
-
-
Mashup Score: 2Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges - 2 year(s) ago
Abstract. Large-scale clinical trials are essential in cardiology and require rapid, accurate publication, and dissemination. Whereas conference presentations,
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges. Read the latest State of the Heart Review in #EHJ: https://t.co/eJbTcs7lMw #publication #trial #dissemination #data #cardiotwitter @escardio @ESC_Journals https://t.co/sHYaN4MJiB
-
-
Mashup Score: 0
Cardiac and pulmonary rehabilitation programs are grossly underutilized, and participation is particularly low in rural regions.We are conducting a 2-…
Source: www.sciencedirect.comCategories: Latest Headlines, PulmonologyTweet-
Stepped care versus center-based #cardiopulmonary #rehabilitation for older frail adults living in #rural MA: Design of a feasibility randomized controlled #trial https://t.co/Z3QjAGjgFX https://t.co/Oh6oYe3TMP
-
-
Mashup Score: 0
May 10, 2023 — A small randomized trial in patients with post-COVID syndromehas found that hyperbaric oxygen therapy promotes restoration of the heart’s ability to contract properly. The research is presented at EACVI 2023, a scientific congress of the European Society of Cardiology (ESC).1 “The study suggests that hyperbaric oxygen therapy can be beneficial in patients with long COVID,” said…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @escardio The randomized controlled double-blind #trial evaluated the effect of #hyperbaric #oxygentherapy (#HBOT) on the #cardiac function of #longCOVID patients: https://t.co/y6vqwVgeOZ #COVID19
-
In Current Issue! An #Electronic Shared #DecisionMaking #App to Improve #Asthma #Outcomes: A Randomized Controlled #Trial https://t.co/6AUGDWq27x https://t.co/k3k2Sr2Pki